Skip to main content

Modelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systems

  • C. J. E. METCALF (a1), P. KLEPAC (a1), M. FERRARI (a2) (a3), R. F. GRAIS (a4), A. DJIBO (a5) and B. T. GRENFELL (a1) (a3)...

Measles vaccine efficacy is higher at 12 months than 9 months because of maternal immunity, but delaying vaccination exposes the children most vulnerable to measles mortality to infection. We explored how this trade-off changes as a function of regionally varying epidemiological drivers, e.g. demography, transmission seasonality, and vaccination coverage. High birth rates and low coverage both favour early vaccination, and initiating vaccination at 9–11 months, then switching to 12–14 months can reduce case numbers. Overall however, increasing the age-window of vaccination decreases case numbers relative to vaccinating within a narrow age-window (e.g. 9–11 months). The width of the age-window that minimizes mortality varies as a function of birth rate, vaccination coverage and patterns of access to care. Our results suggest that locally age-targeted strategies, at both national and sub-national scales, tuned to local variation in birth rate, seasonality, and access to care may substantially decrease case numbers and fatalities for routine vaccination.

Corresponding author
*Author for correspondence: Dr C. J. E. Metcalf, Department of Ecology and Evolutionary Biology, Eno Hall, Princeton University, Princeton NJ 0854, USA. (Email:
Hide All
1. Gans, HA, et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months Journal of the American Medical Association 1998; 280: 527532.
2. Redd, SC, et al. Comparison of vaccination with measles-mumps rubella vaccine at 9, 12 and 15 months of age. Journal of Infectious Diseases 2004; 189: S116122.
3. Halsey, NA, et al. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illness. New England Journal of Medicine 1985; 313: 544549.
4. Ceyhan, M, et al. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months as compared to monovalent measles vaccination of children at nine months followed by MMR revaccination at fifteen months of age. Vaccine 2001; 19: 44734478.
5. Marks, JS, Halpin, TJ, Orenstein, WA. Measles vaccine efficacy in children previously vaccinated at 12 months of age. Pediatrics 1978; 62: 955960.
6. Singh, R, et al. Immune response to measles, mumps and rubella vaccine at 9, 12 and 15 months of age. Indian Journal of Medical Research 1994; 100: 155159.
7. Wolfson, LJ, et al. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007; 369: 191200.
8. Wolfson, LJ, et al. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. International Journal of Epidemiology 2009; 38: 195205.
9.WHO/UNICEF. Measles mortality reduction and regional elimination: strategic plan 2001–2005. Geneva: WHO/UNICEF, 2001.
10. Rosenthal, SR, Clements, CJ. Two dose measles vaccination schedules. Bulletin of the World Health Organization 1993; 71: 421428.
11. Grais, RF, et al. Unacceptably high mortality related to measles epidemics in Niger, Nigeria and Chad. PLoS Medicine 2007; 4: e16.
12. Clark, A, Sanderson, C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009; 373: 15431549.
13.WHO/UNICEF. Joint Annual Measles Report, 2008.
14. Bauch, CT, Szusz, E, Garrison, LP. Scheduling of measles vaccination in low-income countries: Projections of a dynamic model. Vaccine 2009; 27: 40904098.
15. Garly, ML, et al. Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy. International Journal of Epidemiology 1999; 28: 347352.
16. Earn, DJD, et al. A simple model for complex dynamical transitions in epidemics. Nature 2000; 287: 667670.
17. Ferrari, MJ, et al. The dynamics of measles in sub-Saharan Africa. Nature 2008; 451: 679684.
18. Klepac, P, et al. Stage structured transmission of phocine distemper virus in the Dutch 2002 outbreak. Proceedings of the Royal Society of London, Series B 2009; 276: 24692476.
19. Klepac, P, Caswell, H. The stage-structured epidemic: linking disease and demography with a multi-state matrix model approach. Theoretical Ecology (in press).
20. Bjørnstad, ON, Finkenstädt, B, Grenfell, BT. Endemic and epidemic dynamics of measles: Estimating epidemiological scaling with a time series SIR model. Ecological Monographs 2002; 72: 169184.
21. Finkenstädt, B, Grenfell, BT. Time series modelling of childhood diseases: a dynamical systems approach. Journal of the Royal Statistical Society, Series C 2000; 49: 187205.
22. Grenfell, BT, Bjørnstad, ON, Finkenstädt, BF. Dynamics of measles epidemics. Scaling noise, determinism and predictability with the time series SIR model. Ecological Monographs 2002; 72: 185202.
23. Glass, K, Xia, Y, Grenfell, BT. Interpreting time-series analyses for continuous-time biological models-measles as a case study. Journal of Theoretical Biology 2003; 223: 1925.
24. Ferrari, MJ, et al. Episodic outbreaks bias estimates of age specific force of infection: a corrected method using measles in Niamey, Niger as an example. Epidemiology and Infection 2010; 138: 108116.
25. Edmunds, WJ, et al. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiology and Infection 2000; 125: 635650.
26. Schenzle, D. Estimation of the basic reproduction number for infectious diseases from age-stratified serological survey data. IMA Journal of Mathematics Applied in Medicine and Biology 1984; 1: 161191.
27.WHO. Life tables. World Health Organization, 2008.
28. Altintas, DU, et al. The modification in measles vaccination age as a consequence of the earlier decline of transplacentally transferred antimeasles antibodies in Turkish infants. European Journal of Epidemiology 2004; 12: 647648.
29. Klinge, J, et al. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9–11, 12–14 or 15–17 months of age. Vaccine 2000; 18: 31343140.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed